INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE

(19)

(11)

EP 3 678 649 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 2 (W2 B1)

(48)	Corrigendum issued on:
	21.12.2022 Bulletin 2022/51

(45)	Mention of the grant of the patent:
	26.10.2022 Bulletin 2022/43

(21)	Application number: 19751807.9

(22)	Date of filing: 06.02.2019

(51)

International Patent Classification (IPC):

A61K 31/137^(2006.01)
A61K 47/26^(2006.01)

A61K 9/08^(2006.01)
A61P 27/14^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	A61K 9/0043; A61K 47/26; A61P 27/14; A61P 37/08; A61K 31/137

(86)	International application number:
	PCT/US2019/016918

(87)	International publication number:
	WO 2019/157099 (15.08.2019 Gazette 2019/33)

(54)	INTRANASAL EPINEPHRINE FORMULATIONS AND METHODS FOR THE TREATMENT OF DISEASE INTRANASALE EPINEPHRIN-FORMULIERUNGEN UND VERFAHREN ZUR BEHANDLUNG VON ERKRANKUNGEN FORMULATIONS D'ÉPINÉPHRINE INTRANASALE ET MÉTHODES DE TRAITEMENT D'UNE MALADIE

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:
	BA ME
	Designated Validation States:
	KH MA MD TN

(30)

Priority:

06.02.2018 US 201815890131
21.12.2018 US 201862784057 P
14.06.2018 US 201862685049 P
21.09.2018 US 201862734550 P

(43)	Date of publication of application:
	15.07.2020 Bulletin 2020/29

(60)	Divisional application:
	22199817.2

(73)	Proprietors:
	Aegis Therapeutics, LLC San Diego CA 92121 (US) ARS Pharmaceuticals Inc. San Diego, California 92130 (US)

(72)	Inventors:
	LOWENTHAL, Richard San Diego, California 92127 (US) MAGGIO, Edward T. San Diego, California 92121 (US) BELL, Robert G. San Diego, California 92127 (US) SHAH, Pratik San Diego, California 92127 (US)

(74)	Representative: Mewburn Ellis LLP
	Aurora Building Counterslip Bristol BS1 6BX Bristol BS1 6BX (GB)

(56)

References cited: :

WO-A1-2015/095389
US-A- 5 369 095
US-A1- 2015 374 832

WO-A2-2011/139838
US-A1- 2015 005 356
US-A1- 2017 216 199

Chatchawan Srisawat ET AL: "A preliminary study of intranasal epinephrine administration as a potential route for anaphylaxis treatment", Asian Pacific journal of allergy and immunology, 1 March 2016 (2016-03-01), page 38, XP055728595, Thailand Retrieved from the Internet: URL:http://apjai-journal.org/wp-content/up loads/2016/10/27408-39845-6-PB.pdf
NAKPONETONG et al.: "Pharmacokinetics Of Epinephrine Absorption via Intranasal Administration: A Preliminary Report", J ALLERGY CLIN IMMUNOL, vol. 125, no. 2, 2010, XP026902261,
"Adrenalin Chloride Nasal Solution (epinephrine nasal solution, USP", PAR Pharmaceuticals, 2015, XP055631104, Retrieved from the Internet: URL:http://www.parsterileproducts.com/prod ucts/products/adrenalin-chloride-solution. php

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).